TrialHaematologica2016

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.

Haifa Kathrin Al-Ali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.